Curadev reports that the first patient dosed in a Phase 1a/b clinical trial of allosteric sting antagonist CRD3874-SI has completed the first treatment cycle.
Curadev reports that the first patient dosed in a Phase 1a/b clinical trial of allosteric sting antagonist CRD3874-SI has completed the first treatment cycle. PRNewswire February 29, Boston, USA / Noida, Uttar Pradesh, India: Today, Curadev, a firm dedicated to drug discovery and development, announced a noteworthy advancement in its pipeline of immune-system-targeting cancer treatments. … Read more